phospho-ATF2 (Thr51 + Thr53)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 12537R
英文名称phospho-ATF2 (Thr51 + Thr53)
中文名称磷酸化活化复制因子2抗体
别 名ATF2 (phospho T51 + T53); p-ATF2 (phospho T51 + T53); ATF2 (phospho Thr51 + Thr53); p-ATF2 (phospho Thr51 + Thr53); CREB 2; HB 16;Activating Transcription Factor 2; ATF 2; Atf-2; ATF2 protein; cAMP Response Element Binding Protein 2; cAMP response element binding protein CRE BP1; cAMP-dependent transcription factor ATF-2; cAMP-responsive element-binding protein 2; CRE BP1; CRE-BP; CREB 2; CREB2; CREBP1; Cyclic AMP dependent transcription factor ATF 2; Cyclic AMP-responsive; ATF2_HUMAN.
说 明 书100ul
产物类型磷酸化抗体
研究领域细胞生物 转录调节因子 表观遗传学
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-ATF2 (Thr51 + Thr53)抗体交叉反应 Human, Mouse, Rat,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量54kDa
细胞定位细胞核
性 状Lyophilized or Liquid
浓 度1mg/ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human ATF2 around the phosphorylation site of Thr51 + Thr53:DQ(p-T)P(p-T)PT
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-ATF2 (Thr51 + Thr53)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
ATF2 is a member of the ATF/CREB family of basic region leucine zipper DNA binding proteins that regulates transcription by binding to a consensus cAMP response element (CRE) in the promoter of various viral and cellular genes. Many of these genes are important in cell growth and differentiation, and in stress and immune responses. ATF2 is a nuclear protein that binds DNA as a dimer and can form dimers with members of the ATF/CREB and Jun/Fos families. It is a stronger activator as a heterodimer with cJun than as a homodimer. Several isoforms of ATF2 arise by differential splicing. The stable native full length ATF2 is transcriptionally inactive as a result of an inhibitory direct intramolecular interaction of its carboxy terminal DNA binding domain with the amino terminal transactivation domain. Following dimerization ATF2 becomes a short lived protein that undergoes ubiquitination and proteolysis, seemingly in a protein phosphatase-dependent mechanism. Stimulation of the transcriptional activity of ATF2 occurs following cellular stress induced by several genotoxic agents, inflammatory cytokines, and UV irradiation. This activation requires phosphorylation of two threonine residues in ATF2 by both JNK/SAP kinase and p38 MAP kinase. ATF2 is abundantly expressed in brain.
Function:
Transcriptional activator, probably constitutive, which binds to the cAMP-responsive element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Interaction with JUN redirects JUN to bind to CRES preferentially over the 12-O-tetradecanoylphorbol-13-acetate response elements (TRES) as part of an ATF2/JUN complex.
Subunit:
Binds DNA as a dimer and can form a homodimer in the absence of DNA. Can form a heterodimer with JUN. Interacts with SMAD3 and SMAD4. Binds through its N-terminal region to UTF1 which acts as a coactivator of ATF2 transcriptional activity.
Subcellular Location:
Nucleus.
Tissue Specificity:
Abundant expression seen in the brain.
Post-translational modifications:
Phosphorylation of Thr-69 by MAPK14 and MAPK11, and at Thr-71 by MAPK1/ERK2, MAPK3/ERK1, MAPK11, MAPK12 and MAPK14 in response to external stimulus like insulin causes increased transcriptional activity. Phosphorylated by PLK3 following hyperosmotic stress. Also phosphorylated and activated by JNK and CaMK4.
Similarity:
Belongs to the bZIP family. ATF subfamily.
Contains 1 bZIP domain.
Contains 1 C2H2-type zinc finger.
Gene ID:
1386
phospho-ATF2 (Thr51 + Thr53)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-ATF2 (Thr51 + Thr53)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 MMP9 基质金属蛋白酶9抗体
合格 Bax beta BCL2相关X蛋白抗体
合格 合格 CARD15 凋亡加强结构域蛋白15抗体
合格 CARD4 凋亡加强结构域蛋白4抗体
合格 CARD8 凋亡加强结构域蛋白8抗体
合格 TIA1 细胞毒颗粒相关蛋白TIA-1抗体
合格 DDX5/p68 RNA Helicase 三磷酸腺苷依赖解旋酶ddx5抗体
合格 TRIP4 甲状腺**受体相互作用蛋白4抗体
合格 合格 p75 NGF Receptor 神经生长因子受体抗体
合格 MUC5AC 胃粘液素抗体
合格 ZNF238 锌指蛋白238抗体
合格 SNAI3 锌指蛋白293抗体
合格 ZNF408 锌指蛋白408抗体
合格 ZNF419 锌指蛋白419抗体
合格 SUSD4 SUSD4蛋白抗体
合格 SUSD5 SUSD5蛋白抗体
合格 GSK3 Alpha + Beta 糖原合酶激酶3α+β抗体
合格 SIRT2 沉默调节相关蛋白2抗体
合格 合格 CD200R CD200受体抗体
合格 DR5 死亡受体5抗体
合格 ERG3 癌基因ERG3抗体
合格 Melan A 黑色素瘤相关抗原/黑色素-A抗体
合格 phospho-CREB-1 (Thr100) 磷酸化CREB-1抗体
合格 Pepsinogen I 胃蛋白酶原1抗体
合格 Thymidine kinase 1 胸苷激酶1抗体
合格 beta Defensin 3 β防御素3抗体
合格 Histone H4 (tri methyl K20) 组蛋白H4（**基K20）抗体
合格 Pantophysin 突触素样蛋白1抗体
合格 DNA polymerase delta DNA聚合酶δ 抗体
合格 TBC1D15 TBC结构域家族D15蛋白抗体
合格 TBX18 TBX18蛋白抗体
合格 TGFBI 角膜上皮蛋白TGFBI抗体
合格 Histone H3 (acetyl K27) 乙酰化组蛋白H3抗体
合格 合格 合格 phospho-Smad2 (Ser250) 磷酸化细胞信号转导分子SMAD2抗体
合格 PKN1 蛋白激酶C相关激酶1抗体